How to Get Rezdiffra (Resmetirom) in New Jersey

What Is Rezdiffra and Why Does It Matter for New Jersey Patients?

Rezdiffra (resmetirom) is a thyroid hormone receptor beta (THR-β) selective agonist and the first FDA-approved medication for MASH with moderate-to-advanced hepatic fibrosis. The FDA granted approval on March 14, 2024, under the accelerated pathway based on surrogate histological endpoints from MAESTRO-NASH.

New Jersey has one of the higher prevalences of metabolic liver disease in the Northeast. An estimated 24% of the U.S. adult population has MASLD (metabolic dysfunction-associated steatotic liver disease), and roughly 20% of those progress to MASH [1]. That translates to over 1.4 million New Jersey adults who may carry some degree of hepatic steatosis, with a meaningful subset progressing toward fibrosis. Before resmetirom, no pharmacotherapy had an FDA indication for this population. Lifestyle modification and off-label use of pioglitazone or vitamin E were the only options recommended by the American Association for the Study of Liver Diseases (AASLD).

The MAESTRO-NASH phase 3 trial (N=966) demonstrated that resmetirom 80 mg produced MASH resolution without worsening fibrosis in 25.9% of patients at 52 weeks, compared with 9.7% on placebo [1]. The 100 mg dose achieved 29.9% versus 9.7% [1]. A fibrosis improvement endpoint (≥1 stage reduction with no worsening of NASH Activity Score) was met by 24.2% on the 80 mg arm versus 14.2% on placebo [1]. These numbers changed clinical practice overnight.

Telehealth Prescribing in New Jersey: How It Works

New Jersey permits telehealth prescribing of Rezdiffra, and this is often the fastest route to treatment. A board-certified hepatologist, gastroenterologist, endocrinologist, or internal medicine physician can evaluate you by video visit, review your imaging and lab work, and write the prescription electronically.

The state's Telehealth Access Act (P.L. 2020, c.3) requires that telehealth visits meet the same standard of care as in-person encounters. For Rezdiffra, that standard includes confirming the MASH diagnosis, staging fibrosis, and verifying that thyroid function is normal. New Jersey does not require an initial in-person visit before a telehealth prescriber can issue a prescription for a non-controlled substance like resmetirom.

Typical telehealth workflow in NJ:

1. Upload recent labs (liver panel, CBC, thyroid panel, lipid panel) and imaging (FibroScan or MRI-PDFF if available).
2. Complete a synchronous video consultation.
3. The prescriber confirms F2 or F3 fibrosis staging.
4. An electronic prescription is routed to a specialty or 503A pharmacy.
5. Prior authorization (if required by your insurer) is initiated by the prescribing clinic.

Turnaround from first appointment to medication in hand typically ranges from 7 to 21 days, depending on how quickly prior authorization clears. Some commercial insurers in New Jersey approve within 72 hours; others take up to 14 business days.

Required Labs Before Starting Rezdiffra in New Jersey

Every prescriber in New Jersey will need a defined set of laboratory values before writing for resmetirom. The FDA prescribing information specifies baseline thyroid function testing because resmetirom activates THR-β selectively but can still suppress TSH in some patients.

Baseline labs typically include:

• TSH and free T4: resmetirom is contraindicated in patients with decompensated cirrhosis or known thyroid disease that is not adequately managed. The prescribing label recommends checking thyroid function before initiation, at month 1, at month 6, and annually thereafter [2].
• Hepatic panel (ALT, AST, ALP, total bilirubin, albumin): establishes liver injury severity. In MAESTRO-NASH, ALT decreased by a mean of 22% from baseline at the 80 mg dose [1].
• CBC with platelets: a platelet count below 150,000/µL alongside other markers may suggest advanced fibrosis (F3-F4), which changes risk-benefit calculus.
• Lipid panel: resmetirom reduced LDL cholesterol by approximately 14% in the 80 mg group and 19% in the 100 mg group at 52 weeks [1]. Prescribers track this as a secondary benefit marker.
• FibroScan (vibration-controlled transient elastography) or liver biopsy: fibrosis staging is required because the FDA indication is restricted to F2-F3. FibroScan values between 8.0 and 13.9 kPa generally correspond to F2-F3, though biopsy remains the gold standard.

If your labs are more than 6 months old, expect the prescriber to order fresh draws. Many telehealth platforms partner with Quest Diagnostics or LabCorp, both of which have extensive draw-site networks across New Jersey, from Bergen County to Cape May.

Who Can Prescribe Rezdiffra in New Jersey: MD, NP, and PA Scope

Rezdiffra is not a controlled substance. Any clinician with prescriptive authority in New Jersey can write for it. That includes MDs, DOs, nurse practitioners (NPs), and physician assistants (PAs).

New Jersey granted full practice authority to NPs effective July 2022. NPs with the appropriate certification can prescribe resmetirom independently without a collaborative physician agreement. PAs still require a supervising physician relationship under New Jersey law, though the supervision can be remote.

In practice, most Rezdiffra prescriptions originate from hepatologists and gastroenterologists because they are the specialists most likely to manage MASH. The AASLD Practice Guidance on MASLD recommends that pharmacotherapy decisions for MASH be made by or in consultation with clinicians experienced in liver disease staging [3]. A primary care NP or PA who identifies elevated liver enzymes and steatosis on ultrasound will often refer to a GI specialist for fibrosis staging before resmetirom enters the conversation.

If you are seeing a primary care provider in New Jersey and suspect you have MASH, ask specifically about FibroScan referral and fibrosis stage. This single question accelerates the pathway to treatment by several weeks compared with waiting for serial imaging.

New Jersey Pharmacy Options: Specialty and 503A

Rezdiffra is distributed through specialty pharmacy channels. Madrigal Pharmaceuticals initially limited distribution to select pharmacies to manage the launch, though access has expanded. In New Jersey, patients have two primary dispensing routes.

Specialty pharmacies contract directly with Madrigal and handle insurance verification, copay assistance enrollment, and shipment. Major specialty pharmacies serving NJ include Optum Specialty Pharmacy, CVS Specialty, and Accredo. These pharmacies ship directly to your home via cold-chain or standard packaging (resmetirom is stored at room temperature, which simplifies logistics).

503A compounding pharmacies in New Jersey are licensed by the New Jersey Board of Pharmacy and can compound resmetirom pursuant to a patient-specific prescription. A 503A pharmacy fills prescriptions one patient at a time and cannot distribute without a valid prescription in hand. This route may offer cost flexibility for patients paying out of pocket, though compounded medications are not AB-rated equivalents of the commercial product.

The wholesale acquisition cost (WAC) for branded Rezdiffra is approximately $47,400 per year [4]. With insurance, out-of-pocket costs vary widely. Madrigal's patient assistance program, REZDIFFRA Connect, may reduce copays to as little as $0 for commercially insured patients who qualify. NJ Medicaid covers Rezdiffra with prior authorization, as confirmed by the state's Preferred Drug List.

Prior Authorization in New Jersey: What Insurers Require

Most commercial plans and NJ Medicaid require prior authorization (PA) for Rezdiffra. The PA process verifies that the prescribing indication matches the FDA label and that the patient meets specific clinical criteria.

Standard documentation for NJ prior authorization includes:

• Confirmed diagnosis of MASH: supported by biopsy or a validated noninvasive combination (FibroScan plus NFS or FIB-4 score).
• Fibrosis stage F2 or F3: the FDA indication does not cover F0-F1 (too early) or F4/decompensated cirrhosis (excluded from trials due to safety concerns).
• Baseline thyroid function within normal limits: or documentation of adequately treated thyroid disease.
• Documentation that lifestyle modification has been attempted: some insurers require evidence of at least 6 months of diet and exercise counseling prior to pharmacotherapy approval.
• Prescriber specialty or consultation note: certain NJ insurers fast-track PAs when a hepatologist or gastroenterologist is the prescriber of record.

Denial rates vary. The most common reason for PA denial in the first year of Rezdiffra availability has been insufficient fibrosis documentation. If your initial claim is denied, your prescribing team can file a peer-to-peer review. The New Jersey Department of Banking and Insurance requires insurers to process internal appeals within 30 days for non-urgent requests.

Dr. Zobair Younossi, a hepatologist who has published extensively on NASH/MASH health economics, noted in a 2024 interview: "The biggest barrier to resmetirom access is not the drug itself. It is the gap between primary care identification of fatty liver and appropriate fibrosis staging. Patients who arrive at the pharmacy counter with complete documentation rarely face prolonged delays" [5].

Transferring a Rezdiffra Prescription to New Jersey

If you are moving to New Jersey or temporarily residing in the state, your existing Rezdiffra prescription can transfer. New Jersey accepts prescription transfers from all 50 states for non-controlled medications. Your current pharmacy can initiate the transfer electronically or by phone to any licensed NJ pharmacy.

Two practical notes on transfers:

1. Insurance network changes: if your move involves a new insurance plan, the PA process may need to restart under the new plan's formulary rules. Begin this process before your current supply runs out. A 30-day buffer is ideal.
2. Telehealth continuity: if your original prescriber is licensed in New Jersey (many hepatologists hold licenses in multiple states), they can continue managing your care remotely. If not, you will need to establish care with a New Jersey-licensed provider. New Jersey does not restrict prescription transfers based on the originating prescriber's state of licensure, but ongoing refills require an NJ-licensed clinician.

Clinical Monitoring After Starting Rezdiffra

Once you begin resmetirom, your New Jersey prescriber will follow a monitoring schedule aligned with the FDA label and AASLD recommendations.

Month 1: repeat TSH and free T4. In MAESTRO-NASH, TSH suppression below the lower limit of normal occurred in approximately 10% of patients on the 100 mg dose [1]. If TSH drops below 0.5 mIU/L with symptoms, dose reduction or discontinuation may be warranted [2].

Month 3: repeat hepatic panel. A persistent rise in ALT of more than 3 times the upper limit of normal requires evaluation for alternative causes and possible drug discontinuation [2].

Month 6: repeat TSH, free T4, hepatic panel, and lipid panel. This visit is also when many prescribers repeat FibroScan to assess early response. The AASLD notes that noninvasive test improvement at 6 months correlates with histological benefit, though confirmation requires longer follow-up [3].

Annually: comprehensive metabolic panel, thyroid function, lipid panel, and FibroScan or MRE (magnetic resonance elastography). The MAESTRO-NASH confirmatory outcome trial evaluating long-term liver-related clinical events is expected to read out in 2028 [6].

Dr. Arun Sanyal, principal investigator of MAESTRO-NASH and professor at Virginia Commonwealth University, stated: "Resmetirom is the first therapy where we have clear histological evidence of MASH resolution and fibrosis improvement in a randomized setting. The monitoring burden is modest compared with the disease trajectory we are altering" [7].

Side Effects and Safety Considerations

Resmetirom was generally well tolerated in MAESTRO-NASH. The most common adverse events in the 80 mg and 100 mg groups were diarrhea (26.8% vs. 16.8% placebo) and nausea (22.1% vs. 12.7% placebo) [1]. GI symptoms were typically mild, peaked in the first 4 weeks, and resolved without dose adjustment in most patients.

Serious adverse events occurred at similar rates across treatment and placebo arms. There were no cases of overt thyrotoxicosis in the trial. Drug-induced liver injury (DILI) was not identified as a signal, though ALT elevations above 5x ULN occurred in 0.4% of treated patients [2].

Patients on levothyroxine should be aware that resmetirom can alter thyroid hormone metabolism. The FDA label recommends monitoring TSH 4 to 8 weeks after any levothyroxine dose change in patients taking both medications concurrently [2]. This is relevant in New Jersey, where hypothyroidism prevalence tracks the national average of approximately 4.6% of adults over age 12, per NHANES data.

Patients with a body weight under 100 kg should take the 80 mg tablet. Those at or above 100 kg take the 100 mg tablet. Dose is not titrated based on response. It is binary, weight-based.

Cost, Copay Assistance, and NJ-Specific Programs

The annual WAC of Rezdiffra is roughly $47,400, but actual out-of-pocket cost depends heavily on your coverage.

Commercial insurance: most NJ-based commercial plans (Horizon Blue Cross Blue Shield, Aetna, UnitedHealthcare, Cigna) have added Rezdiffra to specialty tiers with prior authorization requirements. Copays before assistance often range from $100 to $500/month. Madrigal's REZDIFFRA Connect program can reduce this to $0 for eligible patients with commercial insurance [4].

NJ Medicaid (NJ FamilyCare): Rezdiffra is covered under the state's Preferred Drug List with mandatory PA. Copays for Medicaid beneficiaries in New Jersey are capped at $1 to $3 per prescription depending on the plan tier.

Medicare Part D: coverage varies by plan. Many Part D plans initially placed Rezdiffra on Tier 5 (specialty), where cost-sharing can reach 25 to 33% until the catastrophic coverage threshold is met. The Inflation Reduction Act's $2,000 annual out-of-pocket cap on Part D drugs, effective since 2025, benefits Medicare patients taking Rezdiffra [8].

Uninsured or underinsured: Madrigal offers a separate Patient Assistance Program (PAP) that may provide Rezdiffra at no cost for patients who meet income eligibility criteria, typically at or below 400% of the federal poverty level.